Leachim (Travoprost)

Travoprost binds to prostaglandin F2α (FP) receptors in the eye, stimulating the uveoscleral pathway. This increases the outflow of aqueous humor from the anterior chamber, leading to a reduction in intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Leachim is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for travoprost in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding mothers should consult their healthcare provider before use.

To request Leachim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leachim (travoprost) belongs to the prostaglandin analog class, similar to latanoprost and bimatoprost. All three lower intra‑ocular pressure by enhancing uveoscleral outflow, but individual response, side‑effect profiles and dosing convenience may differ, making clinician selection based on patient tolerance and efficacy.

Leachim should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Leachim is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid touching the tip of the bottle to any surface.

Serious risks include severe ocular inflammation, allergic reactions, acute angle‑closure glaucoma, sudden vision loss, and rare cases of macular edema. Patients should seek immediate medical attention if they experience intense eye pain, rapid vision changes, or signs of infection.

Leachim is contraindicated in patients with active ocular inflammation, infection, or a known hypersensitivity to travoprost or any component of the formulation. Individuals with a history of severe allergic reactions to prostaglandin analogs should also avoid its use.